Biomarkers /
PRKCI
Overview
Protein kinase C, iota (PRKCI) is a gene that encodes a serine/threonine protein kinase that plays a role in microtubule dynamics in the early secretory pathway. Missense mutations, synonymous mutations, frameshift deletions, frameshift insertions, and nonsense mutations are observed in cancers such as colon cancer, skin cancer, and salivary gland cancer.
PRKCI is altered in 1.86% of all cancers with lung adenocarcinoma, squamous cell lung carcinoma, colon adenocarcinoma, high grade ovarian serous adenocarcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in PRKCI are PRKCI Amplification (0.82%), PRKCI T276fs (0.11%), PRKCI R480C (0.06%), PRKCI Fusion (0.04%), and PRKCI A236S (0.04%) [3].
Clinical Trials
Significance of PRKCI in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.